Using cimetidine to mitigate cisplatin-induced ototoxicity.

Authors

Rahul Sinha
Si Ja Liu
Rebekah Lee
Julia Boyd
Kyla Geary
Dianzheng Zhang

Document Type

Article

Publication Date

4-1-2025

Abstract

Given the well-established role of organic cation transporter 2 (OCT2) in cisplatin uptake to the inner ear cells, and the fact that cimetidine is an FDA-approved drug with well-established inhibitory activity against OCT2, we hypothesized that inhibiting OCT2-mediated cisplatin uptake with cimetidine could eliminate or alleviate cisplatin-mediated ototoxicity. Our preliminary data showed that cisplatin can reduce the viability of House Ear Institute-Organ of Corti 1 (HEI-OC1) cells in a dose-dependent manner, and cimetidine can effectively counteract this cisplatin-induced toxicity without affecting cisplatin's effect on cancer cells. Therefore, combined application of these drugs could ameliorate cisplatin ototoxicity with minimal impact on their anti-cancer effect.

Publication Title

Toxicology in vitro

Volume

104

PubMed ID

39947413

Comments

This article was published in Toxicology in Vitro, Volume 104.

The published version is available at https://doi.org/10.1016/j.tiv.2025.106025.

Copyright © 2025 Published by Elsevier Ltd.

Recommended Citation

Sinha, Rahul; Liu, Si Ja; Lee, Rebekah; Boyd, Julia; Geary, Kyla; and Zhang, Dianzheng, "Using cimetidine to mitigate cisplatin-induced ototoxicity." (2025). PCOM Scholarly Works. 2302.
https://digitalcommons.pcom.edu/scholarly_papers/2302 DOI: https://doi.org/10.1016/j.tiv.2025.106025